BR112016005271A2 - Moduladores de canais de sódio para o tratamento da dor e do diabetes - Google Patents

Moduladores de canais de sódio para o tratamento da dor e do diabetes Download PDF

Info

Publication number
BR112016005271A2
BR112016005271A2 BR112016005271-4A BR112016005271A BR112016005271A2 BR 112016005271 A2 BR112016005271 A2 BR 112016005271A2 BR 112016005271 A BR112016005271 A BR 112016005271A BR 112016005271 A2 BR112016005271 A2 BR 112016005271A2
Authority
BR
Brazil
Prior art keywords
pain
diabetes
treatment
compounds
modulators
Prior art date
Application number
BR112016005271-4A
Other languages
English (en)
Inventor
Babich Olga
Garyantes Tina
Z. LUO Robert
J. PALLING David
P. VENKATACHALAN Srinivasan
Wang-Fischer Yanlin
Original Assignee
Chromocell Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromocell Corporation filed Critical Chromocell Corporation
Publication of BR112016005271A2 publication Critical patent/BR112016005271A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

resumo moduladores de canais de sódio para o tratamento da dor e do diabetes são fornecidos na presente invenção compostos moduladores dos canais de sódio, em particular, compostos moduladores de nav1,7 de fórmula i ou compostos de fórmula i’:   fórmula (i)/fórmula (i'). em particular, são fornecidos aqui processos para a preparação de intermediários usados na preparação de composições farmacêuticas, que compreendem, e métodos terapêuticos que compreendem a administração de, tais compostos. em particular, são fornecidos na presente invenção compostos para o tratamento da dor e diabetes.
BR112016005271-4A 2013-09-10 2014-09-09 Moduladores de canais de sódio para o tratamento da dor e do diabetes BR112016005271A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876046P 2013-09-10 2013-09-10
US61/876,046 2013-09-10
PCT/US2014/054764 WO2015038533A2 (en) 2013-09-10 2014-09-09 Sodium channel modulators for the treatment of pain and diabetes

Publications (1)

Publication Number Publication Date
BR112016005271A2 true BR112016005271A2 (pt) 2020-05-12

Family

ID=52666496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016005271-4A BR112016005271A2 (pt) 2013-09-10 2014-09-09 Moduladores de canais de sódio para o tratamento da dor e do diabetes

Country Status (18)

Country Link
US (2) US20160221974A1 (pt)
EP (1) EP3043787B1 (pt)
JP (1) JP6445565B2 (pt)
KR (1) KR20160054570A (pt)
CN (1) CN105611923B (pt)
AU (1) AU2014318979B2 (pt)
BR (1) BR112016005271A2 (pt)
CA (1) CA2922851C (pt)
ES (1) ES2687598T3 (pt)
IL (1) IL244506B (pt)
MX (1) MX2016002881A (pt)
MY (1) MY181928A (pt)
PH (1) PH12016500296A1 (pt)
RU (1) RU2016113156A (pt)
SG (2) SG11201601367QA (pt)
UA (1) UA120353C2 (pt)
WO (1) WO2015038533A2 (pt)
ZA (1) ZA201702410B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6449845B2 (ja) * 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
WO2016040315A1 (en) * 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes
KR20180095598A (ko) 2015-12-18 2018-08-27 머크 샤프 앤드 돔 코포레이션 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 히드록시알킬아민- 및 히드록시시클로알킬아민-치환된 디아민-아릴술폰아미드 화합물
US10246453B2 (en) 2016-05-20 2019-04-02 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN106084535A (zh) * 2016-06-02 2016-11-09 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆的制备方法
CN105924843A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种耐刮擦的电力电缆
CN105924670A (zh) * 2016-06-02 2016-09-07 扬州兰都塑料科技有限公司 一种电力电缆用耐磨剂
CA3042004A1 (en) 2016-12-09 2018-06-14 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN106892845B (zh) * 2017-02-28 2018-10-30 四川同晟生物医药有限公司 一种2,4-二氨基丁酸衍生物及其制备方法
WO2019200369A1 (en) * 2018-04-13 2019-10-17 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
AU2019331005B2 (en) 2018-08-31 2024-03-28 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
CA3104913A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356897A (en) 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines
CA2440760C (en) * 2001-03-14 2010-02-09 Matthias Gerlach Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
JP4881559B2 (ja) 2002-06-27 2012-02-22 ノボ・ノルデイスク・エー／エス 治療薬としてのアリールカルボニル誘導体
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
AU2005245386B2 (en) 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
JP4056081B1 (ja) * 2004-07-23 2008-03-05 ファイザー・インク ピリジン誘導体
RS20070076A (en) 2004-10-29 2008-09-29 Astrazeneca Ab., Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
PL1966130T3 (pl) * 2005-12-23 2014-05-30 Zealand Pharma As Zmodyfikowane związki mimetyczne lizyny
CA2677493A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
US8853250B2 (en) 2007-07-13 2014-10-07 Icagen, Inc. Sodium channel inhibitors
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
KR101605061B1 (ko) 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
WO2011133729A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
JP5830534B2 (ja) * 2010-07-09 2015-12-09 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのｎａｖ１．７阻害薬としてのスルホンアミド誘導体
KR20140009311A (ko) 2011-01-18 2014-01-22 암젠 인크 Nav1.7 넉아웃 마우스 및 이의 용도
UY34171A (es) * 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
EP2744805A1 (en) 2011-08-17 2014-06-25 Amgen Inc. Heteroaryl sodium channel inhibitors
EP2758053A1 (en) * 2011-09-21 2014-07-30 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
JP6449845B2 (ja) * 2013-03-15 2019-01-09 クロモセル コーポレイション 疼痛の処置のためのナトリウムチャネルモジュレーター
HRP20201701T8 (hr) 2013-09-09 2022-01-07 Peloton Therapeutics, Inc. Aril eteri i njihove uporabe
AU2014318979B2 (en) 2013-09-10 2019-03-28 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
WO2016040315A1 (en) 2014-09-09 2016-03-17 Chromocell Corporation Selective nav1.7 inhibitors for the treatment of diabetes

Also Published As

Publication number Publication date
CN105611923A (zh) 2016-05-25
KR20160054570A (ko) 2016-05-16
US20160130239A1 (en) 2016-05-12
AU2014318979A1 (en) 2016-03-03
RU2016113156A (ru) 2017-10-16
US20160221974A1 (en) 2016-08-04
EP3043787A2 (en) 2016-07-20
UA120353C2 (uk) 2019-11-25
IL244506A0 (en) 2016-04-21
CA2922851A1 (en) 2015-03-19
RU2016113156A3 (pt) 2018-07-02
MX2016002881A (es) 2016-04-21
EP3043787B1 (en) 2018-09-05
JP6445565B2 (ja) 2018-12-26
SG11201601367QA (en) 2016-03-30
WO2015038533A2 (en) 2015-03-19
MY181928A (en) 2021-01-14
ZA201702410B (en) 2019-06-26
ES2687598T3 (es) 2018-10-26
IL244506B (en) 2020-02-27
SG10201805552PA (en) 2018-08-30
US9458118B2 (en) 2016-10-04
CN105611923B (zh) 2019-08-23
JP2016532716A (ja) 2016-10-20
PH12016500296A1 (en) 2016-05-16
AU2014318979B2 (en) 2019-03-28
WO2015038533A3 (en) 2015-10-29
EP3043787A4 (en) 2017-02-01
CA2922851C (en) 2023-03-14

Similar Documents

Publication Publication Date Title
BR112016005271A2 (pt) Moduladores de canais de sódio para o tratamento da dor e do diabetes
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112018006448A2 (pt) derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
BR112014016672A8 (pt) compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
BR112015027704A2 (pt) Composto, uso do mesmo e composição farmacêutica antibacteriana
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
BR112014022214A2 (pt) fenólicos antibacterianos
EA201591371A1 (ru) Пиридиновые производные в качестве легкоразлагаемых ингибиторов rock
MX2014002668A (es) Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas.
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112016006994A2 (pt) inibidores de erk e métodos de uso
BR112018003827A2 (pt) composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112015019412A2 (pt) inibidores de bace1
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112019024566A2 (pt) inibidores de pirazol magl
BR112015006738A2 (pt) terapia de combinação usando belinostat e trabectedina
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2640 DE 10-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.